The effect of tamoxifen on the growth of malignant melanoma was investigated using human cell lines and single-cell suspensions prepared from patients' tumours cultured in soft agar. Tamoxifen stimulated both [3H]-thymidine incorporation and cell numbers in all of the cell lines tested. Cytoplasmic oestrogen receptor (ER) was detected in one of the responding lines and progesterone receptor (PR) in another. Tumour colony formation in soft agar culture was satisfactorily established from tumour cell suspensions from 13 of 21 patients, only one of which had detectable cytoplasmic ER. Greater than 50% reduction in colony formation with 5 X 10(-7) M tamoxifen occurred in two tumours, neither of which contained ER. These results indicate that tamoxifen has the potential to either retard or accelerate the growth of human malignant melanoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0277-5379(84)90220-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-melanogenic effects of hydroxyethyl chrysin through the inhibition of tyrosinase activity: and approaches.
Heliyon
January 2025
Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, 56212, Republic of Korea.
The suppression of tyrosinase (TYR), a key enzyme in melanogenesis, has been suggested as an effective strategy for preventing melanin accumulation. We previously discovered the novel chrysin derivative hydroxyethyl chrysin (HE-chrysin) through an irradiation technique, which exerted higher anti-inflammatory and anti-cancer activities than original chrysin. In the present study, we explored whether HE-chrysin has antioxidant and anti-melanogenic capacity using B16F10 murine melanoma cells and molecular docking.
View Article and Find Full Text PDFA comprehensive outline of the role of non-coding RNAs in vitiligo.
Biochem Biophys Rep
March 2025
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Vitiligo is a common skin depigmentation condition caused by selective destruction of melanocytes. It is regarded as a polygenic disorder. In addition to protein-coding loci, non-coding regions of the genome contribute to the pathogenesis of vitiligo.
View Article and Find Full Text PDFA rare case of malignant melanoma presenting as anterior-superior mediastinal mass.
Radiol Case Rep
March 2025
Thoracic Surgery Unit, Cardiovascular and Thoracic Department, Policlinic University Hospital, University of Messina, Policlinico G. Martino, Messina, Italy.
Mediastinum, as site for malignant melanoma, is extremely rare, both as a primary or metastatic lesion. We present an extremely rare case of primary melanoma presenting as an anterior-superior mediastinal mass in a 65 years-old woman who went to the hospital for neurological symptoms due to unknown metastatic brain melanomas.
View Article and Find Full Text PDFPulmonary and serum cytokine profiles of patients with anti-ARS and anti-MDA5 antibodies.
J Autoimmun
January 2025
Department of Rheumatology, Dokkyo Medical University, Mibu, Tochigi, 321-0293, Japan.
The present study aimed to determine the pulmonary cytokine profiles of patients with anti-RNA synthetase (ARS) and anti-melanoma differentiation-associated protein 5 (MDA5) antibodies. The study included patients with ARS and MDA5 whose serum or bronchoalveolar fluid (BALF) was available. Sandwich enzyme-linked immunoassay microarray multiplex assay was used to measure 18 cytokine levels in serum and BALF.
View Article and Find Full Text PDFEnhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.
J Exp Clin Cancer Res
January 2025
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!